Objectives: We reviewed the 24 week outcomes of HIV-infected patients from our hospital who had their ART switched to dolutegravir monotherapy on an individual clinical basis.
Introduction
Antiretroviral drugs have improved over time, becoming more effective, simpler and better tolerated. However, for some patients current ART may still be challenging. 1 Patients living longer with HIV infection may develop comorbidities as they get older and these comorbidities require them to take additional medications that may increase the risk of significant interactions with some antiretrovirals. 2 In addition, some patients that started treatment when ART was suboptimal or when few drugs were available may harbour archived resistance, particularly to non-nucleoside reverse transcriptase analogues and lamivudine/emtricitabine due to their lower genetic barrier, but also to some extent to other NRTIs and to PIs as these drugs had been extensively used. 3 Despite better tolerability, some patients may experience direct toxicities with contemporary antiretrovirals (e.g. digestive and metabolic with boosted PIs, renal and bone with tenofovir etc.).
Standard ART contains three drugs, 4, 5 but decreasing the number of antiretrovirals represents a strategy aimed to avoid the negative impact of drug exposure. Our hospital (i.e. Hospital Clinic of Barcelona) is a reference centre caring for .4500 HIV-infected adults by the end of 2014, of whom 10% were treated with PI monotherapy and 20% with dual therapies including one ritonavir-boosted PI or one integrase inhibitor or both; reasons for these non-standards regimens differed among patients, but were overwhelmingly due to limited therapeutic options due to toxicity, interactions or resistance issues. The major concern with boosted PI monotherapy is a risk of viral rebound higher than with standard triple therapy, despite the apparent lack of resistance emergence. 4, 5 In addition, PI monotherapy may still have issues of digestive, metabolic or other PI-related adverse effects and risk of clinically significant interactions due to PI boosters. 6, 7 Dolutegravir has several favourable characteristics resembling those of boosted PIs, including high potency, a high inhibitory quotient and a high barrier to resistance, that make it appealing for monotherapy; however, dolutegravir also has a lack of interference with comorbidities, a low risk of interactions, a longer half-life and is easier to take and better tolerated than boosted PIs. 8 We review in this report the characteristics and 24 week outcomes of HIV-infected patients from our centre who had their ART switched to dolutegravir monotherapy on an individual clinical basis.
Methods

Study population
We conducted a retrospective non-interventional study searching the hospital database for HIV-infected patients in whom the treating physician had switched their ART to 50 mg of dolutegravir once daily for reasons other than virological failure and had ≥24 weeks of follow-up irrespective of maintaining or not dolutegravir monotherapy. Information on the reasons for therapy switch was categorized for the purpose of this study as one or more of the following: antiretroviral-related adverse effects; comorbidities overlapping antiretroviral toxicity; need for chronic non-ART with risk of clinically significant interactions with antiretroviral drugs; or archived resistance compromising antiretroviral efficacy.
Patients had usually been visited at least at 4 and 24 weeks after switching therapy. We collected HIV-related data including: known duration of HIV infection; duration of antiretroviral exposure and viral suppression; AIDS-defining events; prior virological failure or genotypic resistance mutations; history of any toxicity to antiretroviral drugs; comorbidities and current non-HIV therapies; current ART; and immediate reasons for switch. Results of human leucocyte antigen HLA-B*5701 allele testing were collected whenever available; a positive result for the HLA-B*5701 allele was considered as abacavir toxicity for the purpose of this study.
Plasma HIV-1 RNA, CD4 and CD8 cell counts, fasting plasma lipids and creatinine measured at each visit following routine protocols were also collected. The CD4/CD8 ratio was calculated. Plasma HIV-1 RNA was measured with a commercially available PCR assay, which has a detection threshold of 37 copies/mL (VERSANT HIV-1 RNA kPCR Assay, Siemens Healthcare Diagnostics). Plasma lipids included triglycerides and total, HDL and LDL cholesterol; LDL cholesterol was measured indirectly whenever triglycerides were ,400 mg/dL. The total cholesterol/HDL cholesterol ratio was calculated. The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation was used to estimate the glomerular filtration rate.
Using stored serum samples from routine blood tests, high-sensitivity C-reactive protein (hsCRP) was also measured at the time of switch and 24 weeks later. hsCRP was determined by particle-enhanced immunonephelometry (Dade Behring, Marburg, Germany); the intra-assay coefficient of variation was 3.1% and the lowest limit of detection was 0.01 mg/dL.
Ethics
According to the regulations of the Spanish Ministry of Health, 9 this study did not require approval by a research ethics committee.
Outcomes
We assessed the proportion of patients with plasma viral load ,37 copies/mL at 24 weeks by a modified ITT (non-completer ¼failure) analysis. For the purpose of this report, plasma HIV-1 RNA results below the detection threshold at baseline and 24 weeks were further categorized either as 'negative PCR signal' or 'positive PCR signal, but ,37 copies/mL' viraemia according to routine results obtained at the Microbiology Laboratory. 10 We also evaluated changes from baseline to 24 weeks for: CD4 and CD8 cell counts and the CD4/CD8 ratio; fasting plasma lipids, creatinine and estimated glomerular filtration rate (CKD-EPI), and hsCRP; incidence of adverse events; impact on the reasons underlying ART switch; and HIV resistance mutations in plasma and PBMCs in case of virological failure.
In case of viral failure, plasma and PBMCs were tested for HIV reverse transcriptase, protease and integrase resistance mutations by population sequencing (Trugene, Siemens) and ultradeep sequencing (454 GS-Junior platform, Roche), respectively, following routine protocols.
Statistical analysis
Plasma viral load ≥37 copies/mL, discontinuation of dolutegravir monotherapy or loss to follow-up were considered therapeutic failures. Fisher's exact or Wilcoxon signed-rank tests were used to compare proportions and continuous variables, respectively, between 24 weeks and baseline.
Results
Population characteristics
Until 31 July 2015, we identified 33 patients in the hospital database who had their ART switched to 50 mg of dolutegravir once daily as monotherapy according to their treating physician and had a follow-up of ≥24 weeks. Two additional patients were excluded from this report because of detectable HIV-1 RNA at baseline (n¼1) or lack of available data (n¼1). Baseline characteristics 
PI/r, ritonavir-boosted PI; INSTI, integrase strand transfer inhibitor; DRV/r, ritonavir-boosted darunavir; LPV/r, ritonavir-boosted lopinavir; ATV/r, ritonavir-boosted atazanavir; MVC, maraviroc; ABC, abacavir; 3TC, lamivudine; ATV, atazanavir; NVP, nevirapine; TDF, tenofovir; FTC, emtricitabine; RPV, rilpivirine; EFV, efavirenz; ETV, etravirine; RAL, raltegravir; ELVc, elvitegravir/ cobicistat. Rojas et al. Table 1 . In contrast to the whole HIV cohort at our centre, patients on dolutegravir monotherapy were older and there was no sexual predominance. They had been exposed to HIV infection for a long period and approximately one-third of them had prior AIDS-defining events. The median (IQR) CD4 count at diagnosis of HIV infection was 230 (136 -313) cells/mm 3 . Patients had received a median (IQR) of 9 (7 -11) different antiretroviral regimens for a median (IQR) of 19 (17) (18) (19) (20) (21) (22) (23) years. Patients had maintained plasma HIV-1 below the detection threshold for a median (IQR) of 8 (4-13) years. At the time of switch, 22 (67%) patients were receiving a ritonavir-boosted PI-containing regimen (including 18 on monotherapy and 3 on dual therapy), 9 (27%) were receiving a triple NNRTI-based regimen and 2 (6%) were receiving regimens containing integrase inhibitors. Table 2 summarizes antiretroviral regimens at study entry and underlying reasons for switching to dolutegravir monotherapy in each patient. Twenty-five (76%) patients had current or past toxicity to antiretrovirals, 32 (97%) had comorbidities, 28 (85%) were receiving chronic non-ART and 16 (48%) had archived resistance mutations. The immediate reasons for switching ART according to the treating physician were: interactions in 13 (39%) patients (ritonavir, n ¼ 10; nevirapine, n ¼ 2; and rilpivirine, n ¼ 1); gastrointestinal symptoms in 11 (33%) patients; dyslipidaemia in 9 (27%) patients; osteoporosis in 6 (18%) patients; high cardiovascular risk (Framingham score ≥20%) in 3 (9%) patients; cardiovascular disease (myocardial infarction) in 1 (3%) patient; and progression of chronic kidney disease in 1 (3%) patient. Some patients had more than one immediate reason for switching ART.
Virological and immunological response
At 24 weeks, the therapeutic efficacy of dolutegravir monotherapy in this cohort was 97% (95% CI 83% -100%). There were no significant differences in the proportion of patients showing 'negative PCR signal' viraemia between baseline (n ¼ 22, 67%) and at 24 weeks (n ¼26, 79%) (P¼ 0.4075).
One patient had viral failure at week 4 (88 copies/mL; confirmed as 155 copies/mL) and 'positive PCR signal, but ,37 copies/mL' viraemia at baseline. He was a 52-year-old man with known HIV-1 infection for 12 years who had received as many as 10 different regimens with intermittent periods of detectable HIV-1 RNA because of lack of adherence due to multidrug abuse. He had been abstinent of drug abuse and maintained viral suppression for the last 2 years with darunavir/ritonavir monotherapy, but he had comorbidities and risk of potential interactions that made his doctor consider switching his ART. He was also receiving psychotropic therapy including paliperidone, trazodone and lorazepam, antihypertensive therapy including losartan and lipid-lowering therapy including pitavastatin. Previous plasma HIV-1 reverse transcriptase and protease genotypic resistance tests had shown the following mutations: 62V, 106I, 118I, 15V and 63P. He had had previous viral failure to a raltegravir-containing regimen without integrase genotypic resistance testing at that time. After detecting viral failure on dolutegravir monotherapy, he was recommended to increase the dolutegravir dose to 50 mg twice daily, but he continued 50 mg once daily. Plasma HIV-1 RNA remained detectable at 24 weeks DRV/r, ritonavir-boosted darunavir; LPV/r, ritonavir-boosted lopinavir; ATV/r, ritonavir-boosted atazanavir; MVC, maraviroc; ABC, abacavir; 3TC, lamivudine; ATV, atazanavir; NVP, nevirapine; TDF, tenofovir; FTC, emtricitabine; RPV, rilpivirine; EFV, efavirenz; ETV, etravirine; RAL, raltegravir; ELVc, elvitegravir/ cobicistat; PI/r, ritonavir-boosted PI.
(79 copies/mL; confirmed as 101 copies/mL). HIV RNA genotypic resistance tests in confirmation samples at 4 and 24 weeks detected no integrase mutations. HIV DNA genotypic resistance tests detected the integrase mutation 118R in 7% of the integrated DNA in PBMCs at 24 weeks. Figure 1 shows CD4 and CD8 cell counts and the CD4/CD8 ratio at baseline, 4 weeks and 24 weeks. The CD4/CD8 ratio was significantly higher at 24 weeks compared with baseline (P ¼ 0.0404).
Safety and tolerability
Dolutegravir monotherapy was apparently well tolerated. No patient discontinued therapy. Two patients had adverse events reported during follow-up: foot amputation due to chronic ischaemia in a diabetic patient and secondary syphilis. None of these events was attributed to dolutegravir. Table 3 compares selected chemistry parameters between baseline and 24 weeks. There were significant median decreases in triglycerides (2117 mg/dL), total cholesterol (236 mg/dL), the total cholesterol/HDL cholesterol ratio (20.7) and hsCRP (20.05 mg/dL) (P ≤ 0.007), although CKD-EPI also decreased (27.1 mL/min) (P, 0.0001).
Regarding the impact on the immediate reasons for ART switch, there were no clinically evident interactions in the 13 patients who were at risk at baseline, gastrointestinal symptoms improved or disappeared in 9 of 11 patients, plasma lipids improved in the 9 patients with dyslipidaemia at baseline and Framingham score decreased in all 3 patients with high cardiovascular risk at baseline. Two patients with osteoporosis had dual-X absorptiometry conducted at baseline and 24 weeks, but lumbar spine and femur T-scores remained unchanged. In the patient with progression of chronic kidney disease at baseline, estimated glomerular filtration (CKD-EPI) further decreased from 59 to 52 mL/min/1.73 m 2 , but urinary protein/creatinine improved, decreasing from 330 to 146 mg/mg at 24 weeks.
Discussion
This study emerged from the coincidence of two factors in a large cohort of HIV-infected adults receiving clinical care. On the one hand, the numerous difficulties that a number of patients experienced to satisfactorily maintain their ART despite having achieved sustained viral suppression. 1 Characteristics of the patients included in this cohort outlined in Table 2 make evident the multiple limitations that they had and the need for further improvement in their antiretroviral regimens. On the other hand, the availability of an antiretroviral drug such as dolutegravir with characteristics that allowed for potential consideration of monotherapy. 8 Dolutegravir has compared favourably with efavirenz 11 and darunavir/ritonavir 12 and similarly with raltegravir 13 in naive patients and it is currently recommended as a first option for antiretroviral-naive patients. Dolutegravir also compared favourably with raltegravir in patients with viral failure, but no prior exposure to integrase inhibitors.
14 Besides its outstanding efficacy, dolutegravir is also characterized by its high genetic barrier and robustness in the prevention of viral resistance. In antiretroviral-naive patients, 11 -13 dolutegravir-treated patients with viral failure did not show resistance mutations to both dolutegravir and NRTIs, a characteristic known for boosted PIs, but not for antiretrovirals from other drug classes or even the other integrase inhibitors currently available, raltegravir and 
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elvitegravir. This characteristic is also supported by clinical data from antiretroviral-experienced, but integrase inhibitor-naive, patients with viral failure 14 and by laboratory data. 15 Dolutegravir also showed fewer discontinuations than comparator drugs and had no effect on lipids or liver enzymes in antiretroviral-naive patients, although an increase in creatinine can be expected by tubular blockade that is not considered a toxic effect. Dolutegravir is conveniently administered as a single, small pill once daily and with no food restrictions. Dolutegravir does not require boosting and plasma levels have been reported to be above the 90% inhibitory concentration 24 h after dosing. 16 Dolutegravir has no expected major interactions with other drugs, a characteristic also shared by raltegravir. All these factors together make dolutegravir different from the other antiretrovirals available and it may be particularly important for patients with limitations to pre-existing ART.
The results in this cohort of patients who received dolutegravir monotherapy are remarkable, because almost all were able to maintain viral suppression after 24 weeks, with improvements in the immediate reasons that made them have their therapies switched and no deleterious effects on immune function or major adverse events. All patients in the cohort, except for the one who had viral failure, have maintained dolutegravir monotherapy for almost 1 year of follow-up at the time of writing this report and plasma HIV RNA has remained suppressed in all of them. These results are surprising because they would have not been possible with any other single drug. For the last 30 years, the vulnerability to develop resistance has been a serious limitation to every antiretroviral drug. This was why early studies using single and dual combinations produced only very short-term benefits.
We observed one patient developing viral failure in our cohort. This patient had a previous viral failure to a raltegravir-containing regimen, although no resistance mutations to integrase inhibitors were found when viral failure to dolutegravir monotherapy was initially detected. Although this patient denied missing dolutegravir doses, there were reasons to suspect that his adherence to therapy was not optimal. This patient had persistent low-level viraemia and developed mutation 118R in the integrase gene, which confers intermediate resistance to raltegravir and elvitegravir and potential low-level resistance to dolutegravir according to the Stanford University HIV Resistance Database (http://sierra2. stanford.edu/sierra/servlet/JSierra). In another 24 week French cohort study including patients with similar epidemiological characteristics as those in our cohort, 3 (11%) out of 28 patients who switched to dolutegravir monotherapy experienced viral failure with development of resistance mutations to integrase inhibitors. 17 As with the patient who failed in our cohort, all three patients with viral failure in the French study had previously been exposed to integrase inhibitors. These patients had dolutegravir plasma levels measured at several timepoints during follow-up; although they were well above the in vitro 90% inhibitory concentration and within therapeutic levels at the time of viral failure, plasma levels in the weeks or few months before viral failure were not measured and thus we cannot confirm whether optimal adherence to therapy had been continuously maintained in these three failing patients. What it is evident from the French study and from ours is that viral failure to dolutegravir monotherapy may lead to the appearance of resistance mutations to integrase inhibitors and this is something different from what we knew about boosted PI monotherapy. The existence of resistance mutations to raltegravir might cause cross-resistance to dolutegravir, which may result in less positive results when dolutegravir is employed as a second-line maintenance regimen. 18 Although dolutegravir has a high genetic barrier to resistance, it is definitely lower than that of boosted PIs. Both R263K and G118R as single mutations can confer resistance to dolutegravir 19 and resistance may be even higher when secondary mutations are also present. 20 Dolutegravir-containing monotherapy and dual therapy 17,21 -23 are non-standard strategies and further research is needed before they can be generalized into the clinical setting.
Our study was not controlled, included a low number of patients and had a short follow-up. We acknowledge that reasons for switching therapy differed among participants and other nonstandard regimens could have been used instead of dolutegravir monotherapy. Limitations with ART in our cohort are exemplified by the common use of non-standard treatments (e.g. monotherapy with boosted PIs) in a substantial number of patients. Patients from our cohort were therefore highly selected and their results may not be applied to other patients. As with any retrospective study, we had no accurate information of potential adverse effects on starting dolutegravir, but we did not identify any patient discontinuing therapy. The major strength for our study is that switching allowed patients to be released from limitations with their previous antiretroviral regimens while they were able to maintain the benefits of sustained viral suppression. 24 In summary, these data suggest the efficacy of dolutegravir monotherapy as a maintenance strategy to be further confirmed in randomized clinical trials. Several studies with monotherapy or dual therapy with dolutegravir have been registered already or are being planned. They will provide us with more definitive data to determine whether dolutegravir monotherapy or dual therapy can challenge the paradigm of standard triple therapy.
